InSilico Medicine

📅 Upcoming

🕒 Recent(90d)

News

• Lilly’s latest China drug deal; Immunovant’s setback in lupus
  Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…
  biopharma_dive · 6d ago
• Deep Dive: How AI is now essential in biopharma
  As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.
  biospace · 8d ago
• Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
  The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."
  biopharma_dive · 14d ago
• Owkin, Servier ink oncology R&D deal to guide discovery and trial design
  AI drug discovery company Owkin has signed a pact with French drugmaker Servier to license Owkin’s AI scientist K Pro across Servier’s oncology discovery and trial operations.
  fiercebiotech · 19d ago
• Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
  While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…
  biospace · 22d ago
• China poses increasing security risk as US biotech innovation edge erodes
  The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winn…
  biospace · 1mo ago
• Research into protein interactions sheds new light on causes of autism
  Studying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists at the University of California, San Francisco has suggested.
  fiercebiotech · 1mo ago
• Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
  After two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, rep…
  biospace · 1mo ago
• After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
  Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of…
  biospace · 1mo ago
• Why Big Pharma is chasing the industry’s most-powerful supercomputer
  Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.
  biopharma_dive · 1mo ago